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Abstract. Background/Aim: A common finding in cancer
cells is the overexpression of histone deacetylases (HDACs),
leading to altered expression and activity of numerous
proteins involved in carcinogenesis. Considering that leptin
can modulate the levels of HDACs, we hypothesised that
leptin receptor antagonists can alter HDAC expression.
Materials and Methods: HDAC expression in cells exposed
to leptin and leptin receptor antagonists (SHLA and Lan2)
were evaluated in ovarian epithelial (OVCAR-3, CaOV3)
and folliculoma (COV434, KGN) cells. Results: Higher
HDAC expression was found in epithelial compared to
folliculoma cells. Leptin increased class I and II HDACs
only in OVCAR-3 cells, and SHLA was more potent then
Lan-2. In folliculoma cells, leptin only increased class II
HDAC expression, Lan-2 was more potent than SHLA in the
COV434 and neither antagonist affected the KGN cells.
Conclusion: SHLA and Lan2 eliminate the negative effects
of leptin on HDAC expression in a cell-type-dependent
manner. This is the first report testing leptin receptor
blockers as HDAC inhibitors in ovarian cancer cells. 
Epigenetic changes such as post-translational histone
modifications can play an important role in cancer
development. Two groups of enzymes are responsible for the
acetylation pattern of histones: histone acetylases (HATs) and
histone deacetylases (HDACs). The predominance of
HDACs over HATs led to repression of the transcription of
several genes responsible for carcinogenesis suppression. In
addition, HDACs are also responsible for the deacetylation
of non-histone proteins which regulate cell-cycle
progression, proliferation and apoptosis (1). Mammalian
HDACs are divided into four classes. HDACs 1, 2, 3 and 8
constitute class I. HDACs 4-7, 9 and 10 form class II. Class
III HDACs are NAD+-dependent enzymes also known as
Sirtuins (SIRTs) (2). HDAC11, the only member of Class IV
HDACs, combines the features of class I and II (3).
A common finding in cancer cells is the overexpression of
HDACs and their increased activity, leading to the altered
expression and activity of numerous proteins involved in
carcinogenesis. Although the knowledge of ovarian cancer is
growing, there is still no proper therapy for the prevention
and treatment of this type of cancer (4). There is a growing
body of evidence showing that the expression of class I
HDACs is increased in ovarian carcinomas (5-7) and this is
suspected not only of playing a significant role in
carcinogenesis, but also of contributing toward resistance to
chemotherapeutic agents used for treating ovarian cancer. Jin
et al. (5) showed that HDACs from class I are overexpressed
in ovarian cancer samples versus samples obtained from
healthy individuals. Hayashi et al. (8) revealed that among
the many tissue samples obtained from ovarian cancer
patients, HDAC1 and HDAC2 are mainly involved in cancer
cell proliferation, while HDAC3 is connected with cell
migration processes. Inhibiting HDAC3 results in the
inhibition of cancer cell migration. In addition, HDAC
expression is increased among patients with ovarian cancer
that is resistant to platinum-based chemotherapy (9). Also,
HDAC4 (9) and HDAC6 (10) are involved in ovarian cancer
resistance and progression. Lapinska et al. (11) showed that
combination therapies with HDAC inhibitors may be
effective against different types of ovarian cancers.
Obesity is a risk factor for several different types of
cancer, significantly promoting cancer incidence,
progression, poor prognosis and resistance to anti-cancer
therapies. The increased risk of ovarian cancer, both
epithelial and folliculoma, are correlated with obesity;
elevated leptin secretion and higher leptin receptor
expression has been described in ovarian cancer versus non-
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cancer cells (12, 13). Although data pointing to the
relationship between HDAC and leptin are scarce, it has
been reported that HDAC5 expression is regulated by dietary
lipids and leptin and hypothalamic HDAC5 is an important
component of leptin signalling (14). One of the histone
deacetylase inhibitors, Valproic acid, can decrease leptin
mRNA in adipocytes, thereby altering leptin homeostasis
(15). Leptin can affect the level of HDACs in pancreatic
adenocarcinoma tumorspheres, and, via the modulation of
HDACs, leptin can induce pancreatic adenocarcinoma
progression and chemoresistance (16). Elevated HDAC1 and
HDAC2 expression was noted after leptin administration in
rats and correlated with a decrease in sperm quality (17).
Sheykhani et al. (18) have shown that leptin can reverse the
apoptotic effect of trichostatin A (an inhibitor of first and
second class HDACs) on buffalo oocytes. 
In our previously published data, we demonstrated that the
negative effect of leptin on the proliferation of several
epithelial and folliculoma ovarian cancer cells can be
partially or completely reversed by leptin receptor antagonist
treatment via interactions with cell cycle protein expression
(12, 13). A number of leptin receptor antagonists have been
synthesised for therapeutic use, with several completing pre-
clinical testing (19) indicating their possible use in anticancer
therapy. HDAC inhibitors seem to be promising anti-cancer
drugs, particularly in combination with other anti-cancer
drugs and/or radiotherapy. 
The question arises whether the leptin receptor blockers
may also have a positive impact on HDACs. As a model for
this study, we used the epithelial ovarian cancer cell lines,
OVCAR-3 and CaOV-3, and folliculoma cell lines KGN and
COV434. First, we determined the basal and leptin-
stimulated expression of HDAC classes I and II and then the
effect of leptin receptor antagonists on the expression of
HDAC genes and proteins. Additionally, we evaluated the
action on HDAC activity.
Materials and Methods
Materials. Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-
12 (DMEM/F-12) was obtained from Gibco by Thermo Fisher
Scientific (Waltham, MA, USA). Dulbecco’s Modified Eagle’s
Medium (DMEM), RPMI-1640, foetal bovine serum (FBS, heat
inactivated), penicillin and streptomycin were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Leptin was obtained from
Sigma Chemical Co. Leptin receptor antagonists (SHLA, Lan1 and
Lan2) were obtained from Protein Laboratories Rehovot (PLR) Ltd.
(Rehovot, Israel). 
Cell culture. OVCAR-3 (established from the malignant ascites of
a patient with progressive adenocarcinoma of the ovary after
combination chemotherapy with cyclophosphamide) and CaOV-3 (a
primary ovarian cancer cell line), were obtained from the American
Type Culture Collection (Manassas, VA, USA). COV434 cells were
obtained from the Sigma Chemical Co. (St. Louis, MO, USA). The
biological characteristics of this cell line have been previously
described (20). KGN cells were obtained from Masatoshi Nomura
and Hajime Nawata, Kyushu University, Japan (21). CaOV-3 cells
were routinely cultured in DMEM with 10% FBS, and OVCAR-3
in RPMI-1640 supplemented with 20% FBS. COV434 cells were
routinely cultured in DMEM + 2 mM Glutamine + 10% FBS. KGN
cells were routinely cultured in DMEM/F-12 + 10% FBS. Cells
were grown in 75 cm2 tissue culture dishes (Nunc, Denmark) in a
37˚C incubator with a humidified mixture of 5% CO2:95% air.
qPCR analysis. Basal HDAC gene expression and the expression of
HDACs genes under the influence of leptin and leptin antagonists was
determined by qPCR. Cells were seeded into 96-well culture plates at
a density of 1.5×104 cells/well (CaOV-3), 1.5×103 cells/well (OVCAR-
3), 8×103 cells/well (COV434) and 1.5×104 cells/well (KGN) taking
into consideration the size of cells and the population doubling time.
The next day, the medium was changed and cells were treated with
leptin at a dose of 40 ng/ml alone or with SHLA and leptin. Doses of
leptin were chosen based on the literature and our previously published
paper (12, 13, 22). Total RNA isolation and cDNA synthesis was
performed using the TaqMan Gene Expression Cell-to-CT Kit (Applied
Biosystems, Carlsbad, CA, USA) in accordance with the
manufacturer’s protocol. Amplifications were performed using the
StepOnePlus system (Applied Biosystems) and the TaqMan starters
(Hs02621185_s1, Hs00231032_m1, Hs00187320_m1, Hs00195
814_m1, Hs00608366_m1, Hs00195869_m1, Hs00248789_m1,
Hs00206843_m1 (Cat. #4453320) in combination with the TaqMan
Gene Expression Master Mix (Applied Biosystems), in accordance with
the manufacturer’s instructions. The relative expression of genes was
normalised against the endogenous reference gene GAPDH (Human
GAPD Endogenous Control, number 4333764F) (ΔCq) and converted
to relative expression using the 2-ΔΔCq method. The results are
expressed as relative values (RQ).
Western blot analysis. Cells were plated into 24-well plates at a
density of 2×105 (CaOV-3), 3.5×104 (OVCAR-3 cells), 4×104
(COV434 cells) and 6×104 (KGN cells) and allowed to attach
overnight. On the following day, the media were changed and cells
were treated with 40 μg/ml leptin alone or in combination with
1,000 μg/mL SHLA or Lan2. To examine HDAC protein expression,
cells were incubated for 48 h. After incubation, cells were washed
with ice-cold PBS and lysed with Laemmli lysis buffer (Sigma
Chemical Co.). The lysed cells were then scraped, transferred to
microtubes and stored at –70˚C until analysis.
Equal amounts of protein (50 μg) from each treatment group
were separated by SDS-PAGE and transferred to PVDF membranes
using the Bio-Rad Mini-Protean 3 apparatus (Bio-Rad Laboratories
Inc., Hercules, CA, USA). Blots were incubated overnight with
primary antibodies specific to HDAC5, HDAC6 and HDAC7
(#20458S, #7558S, #33418S Cell Signaling Technology Inc.,
Beverly, MA, USA) at a 1:1,000 dilution. After incubation with the
primary antibody, membranes were washed three times with 0.1%
Tween-20 in 0.02 M TBS buffer and incubated for 1 h with an anti-
rabbit horseradish peroxidase-conjugated secondary antibody
(#7074 Cell Signaling Technology Inc.; dilution 1:2,000). 
β-Actin was used as an internal loading control; membranes were
incubated overnight with primary antibodies specific to β-actin
(A5316, Sigma Chemical Co.; dilution 1:2000) and for 1 h with a
horseradish peroxidase-conjugated secondary antibody (P0447
DAKO, Glostrup, Denmark; dilution 1:5,000).
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Immunopositive bands were visualised using Western Blotting
Luminol Reagent (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) and ChemiDoc™ XRS+System (Bio-Rad Laboratories Inc.).
Individual protein levels were normalised to β-actin controls and
the ratio of protein to β-actin was normalised to 1 in the untreated
control group.
Histone deacetylase activity assay. HDAC activity was measured
using the In Situ HDAC Activity Fluorometric Assay Kit (EPI003,
Sigma Chemical Co.). The amounts of fluorescent product were
measured using a fluorescence microplate reader (FLx800 Bio-Tek
Instruments, Winooski, VT, USA) at an excitation wavelength of
368 nm and an emission wavelength 442 nm. All samples were run
in quadruplicate at the same assay.
Statistical analysis. Data were expressed as mean±SEM from the
four independent experiments performed in triplicate. Statistical
analyses were performed using GraphPad Prism 5. Data were
analysed using a two-way analysis of variance (ANOVA) followed
by a Tukey’s honestly significant difference (HSD) multiple range
test. A value of p<0.05 was considered statistically significant.
Results 
Effect of leptin and leptin receptor antagonists on HDAC
gene and protein expression in ovarian epithelial cancer
cells. In the OVCAR-3 cell line, the expression of all
investigated HDACs was significantly higher than in CaOV-
3 cells, with the highest expression noted for HDACs 1, 2, 3
and 7 (Figure 1a). Leptin increased the expression of the
HDAC 1, 7 and 9 genes (Figure 1b). From the used blockers,
SHLA not only reversed the stimulatory effect of leptin on
the HDAC 1 and 9 genes and proteins, but also decreased the
expression of the HDAC 4 gene, the HDAC 5 gene and
protein and the HDAC6 protein. Lan-2 had no effect on
HDAC gene expression, but a strong inhibitory effect was
noted on the expression of the HDAC9 protein (Figure 1c-d). 
In CaOV-3 cells, leptin did not have a statistically
significant effect on the expression of any of the investigated
HDAC genes (Figure 1b). From the investigated HDACs,
SHLA decreased the expression of the HDAC4 gene, but not
the protein, and HDAC9 protein expression. Lan-2 increased
the expression of the HDAC 2, 5, 6 and 7 genes (Figure 1e).
An inhibitory effect on protein expression was observed only
in the case of HDAC 5 (Figure 1f).
Effect of leptin and leptin receptor antagonists on HDAC
gene and protein expression in ovarian granulosa cancer
cells. In the COV434 cancer cell line, representing a juvenile
form of granulosa cancer, the highest expression of HDAC9
was noted. For other investigated HDAC genes, the
expression of HDAC 1, 2 and 3 was four- to seven-fold
higher than that of HDAC 4, 5, 6 and 7. The low expression
of all investigated HDACs was observed in KGN cells
representing the adult form of ovarian granulosa cancer
(Figure 2a). In COV434 cells, leptin increased HDAC9 and
had an inhibitory effect on HDAC3, while it increased the
expression of HDAC 5, 6 and 7 in KGN cells (Figure 2b).
SHLA decreased HDAC1 gene expression and the expression
of HDAC 1, 4 and 9 proteins. Lan2 was most potent
antagonist, decreasing the expression of not only the HDAC1
but also the HDAC5 genes and proteins, as well as the
HDAC4 and 9 protein expression (Figure 2c and d). In KGN
cells, leptin increased HDAC 4, 5 and 6 gene expression
(Figure 2b). Both of the antagonists used had no effect on the
investigated HDAC gene expression (Figure 2e).
Effect of leptin and leptin receptor antagonists on histone
deacetylase activity. In epithelial cell lines, the basal activity
of HDAC was higher in OVCAR-3 malignant progressive
adenocarcinoma, than in a primary ovarian cancer cell line
(CaOV-3). In folliculoma cell lines, the basal activity of
HDACs was 2-fold higher in adult (KGN) than in juvenile
(COV434) forms. In all of the tested ovarian cancer cell
lines, neither leptin nor leptin receptor antagonists changed
HDAC activity (Figure 3).
Discussion
The elevated expression of many HDAC class proteins has
been described in 60-90% of ovarian tumours and many
histone- and non-histone-mediated alterations have been
described that alter the balance in favour of cellular growth
and survival (23).
The presented data clearly showed significantly higher
HDAC gene expression in epithelial than in granulosa cells.
Moreover, they showed that in the chemoresistant OVCAR-
3 cell line, the expression of all investigated HDACs was
significantly higher than in primary CaOV-3 cells, with the
highest expression noted for HDACs 1, 2, 3 and 7. In
granulosa tumour cells, lower HDAC expression was
observed in the adult form than in the juvenile form, with
the highest expression of HDAC9 found in COV434 cells.
Except for the high expression of HDAC7 in OVCAR-3 and
HDAC9 in COV434 from class II, in all cases, the
expression of HDACs from I class was higher than from
class II. The majority of studies showed the enhanced
expression of class I HDACs in solid human tumours and in
locally advanced, dedifferentiated, strongly proliferating
tumours. There is a growing body of evidence that the
expression of class I HDACs is increased in ovarian
carcinomas (4), and this is suspected not only of playing a
significant role in carcinogenesis, but also of contributing
towards resistance to chemotherapeutic agents used for
treating ovarian cancer (23). This is in agreement with our
observation that the highest expression was observed in
OVCAR-3 cells.
In COV434, representing the juvenile form, the expression
of HDACs 1, 2 and 3 was higher than that of other HDACs.
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These findings are in agreement with other studies indicating
higher expression of histone deacetylases from group I, not
only in epithelial ovarian cancer, but also in other cancer
types (24-29). HDAC9 has a key role in the development
and differentiation of many types of cells, including
regulatory T cells. Systemic autoimmune diseases such as
lupus, diabetes, and rheumatoid arthritis have dysfunctional
effector T cells; this suggests that HDAC9 may act as an
epigenetic switch in effector T cell-mediated systemic
autoimmunity (30).
The possible action of leptin on HDAC expression in the
ovary and in ovarian cancer is not known. However, it has
been suggested that hypothalamic HDAC5 activity is a
regulator of leptin signalling, which adapts food intake and
body weight to our dietary environment, and that the
overexpression of HDAC5 can increase leptin sensitivity (14).
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Figure 1. Basal gene expression of histone deacetylases (a). Effect of leptin (b) and leptin receptor antagonists on HDAC gene and protein expression
in OVCAR-3 (c, d), and HDAC gene and protein expression in CaOV-3 (e, f) cancer cell lines. Basal mRNA values were evaluated by qPCR after
24 h of cell culture and all the results were normalised to HDAC1 expression in CaOV-3 with a value equal to 1. All values marked with *p<0.05
and **p<0.01 are significantly different from the control values. Values are mean±SEM. All values marked with *p<0.05 are significantly different
from the control. All values marked with #p<0.05 are significantly different from leptin-stimulated cells. 
Recently published data by Tchio et al. (31) indicated that
leptin can only directly act on HDAC4 and HDAC5. However,
leptin can indirectly affect other HDACs by influencing
microRNAs; leptin can increase miR21 (oncogenic
microRNA21), which is able to increase HDAC3 expression,
and the combined action of these factors leads to cancer cell
proliferation (31). Our study is one of the first to show the
cancer cell type-dependent action of leptin on HDAC
expression. In epithelial cancer cells, leptin increased HDAC1
expression (from class I) and HDAC7 and HDAC9 gene
expression (from class II) only in OVCAR-3 cells. In granulosa
tumour cells, leptin increased gene expression only in the class
II HDACs 2, 6 and 7, in KGN and HDAC9 in COV434.
HDAC6 can be used as a marker for cancer prognosis. In
multiple myeloma cells, blocking the expression of HDAC6
can cause apoptosis. In breast cancer MCF-7 cells, HDAC6 can
lead to metastasis by up-regulating cell motility (32). 
The results of the presented data showed a cell type-
dependent action of leptin and leptin receptor antagonists on
HDAC expression. In epithelial OVCAR-3 cells, SHLA was
more potent then Lan-2; SHLA reversed the stimulatory effect
of leptin on HDAC1 and 9, and additionally decreased the
protein expression of HDACs 5, 6 and 9. In CaOV-3,
characterised by low HDAC gene expression and no action of
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Figure 2. Basal expression of histone deacetylase genes (a). Effect of leptin (b) and leptin receptor antagonists on HDAC gene and protein expression
in COV434 cell lines (c, d) and gene expression in KGN cells (e). Basal and leptin-stimulated mRNA values was evaluated by qPCR after 24 h of
cell culture and the results were normalised to HDAC1 expression in COV434 cells with a value equal to 1. All values marked with *p<0.05 and
**p<0.01 are significantly different from control values. Values are mean±SEM. HDAC densitometry results were normalised to β-actin loading
control to obtain band ratios. All values marked with #p<0.05 are significantly different from the values of leptin at 40 ng/mL. 
leptin on HDAC expression, SHLA decreased HDAC4 while
Lan2 had no effect on gene expression, but decreased HDAC9
protein expression. Shen et al. (33) showed that epithelial
ovarian cancer tissues in stage III/IV had higher HDAC4
expression than in stage I/II. They suggest that the
accumulation of HDAC4 induced by fibrillar collagen matrices
in the nucleus via the co-localisation of PP1α leads to the
repression of p21 mRNA/protein and in turn promotes the
proliferation and migration of epithelial ovarian cancer cells.
In granulosa tumour cells, Lan-2 seems to be the most potent
inhibitor. The reverse stimulatory effect of leptin on HDAC9
and inhibitory effect on HDAC3, and also decreased the
expression of HDAC1 and 5 in COV434 cells, while SHLA
decreased only HDAC1 gene expression. Kabra et al. (14)
identified histone deacetylase 5 (HDAC5) as a regulator of
leptin signalling and organismal energy balance. HDAC5
directly regulates STAT3 localisation and transcriptional
activity via reciprocal STAT3 deacetylation at Lys685 and
phosphorylation at Tyr705. In thte KGN cell line, characterised
by very low HDACs expression, no effect of either antagonist
on HDAC gene expression was noted, so actions on protein
expression have not been evaluated. This is in agreement with
Ropero et al. (34), who showed that the treatment of tumours
expressing low levels of HDACs might be ineffective because
it has been shown that HDAC-negative tumours caused by the
mutation of HDAC genes are resistant to HDAC inhibitors. 
Various studies carried out on cell lines derived from
gynaecological malignancies, such as ovarian, breast and
endometrial cancer, have demonstrated that HDAC inhibitors
can inhibit tumour cell growth by suppressing proliferation
and stimulating apoptosis (23, 35). Many known HDAC
inhibitors are used in clinics, supporting conventional
therapies, including for the treatment of ovarian cancer (36).
The pharmacological inhibition of HDAC1, which is
associated with chemoresistance in ovarian cancer cells, can
increase tumour cell sensitivity to immune cells (37).
Nebbioso et al. (38) were able to decrease the expression of
leptin receptor genes in adipocytes using selective inhibitors
against HDACs from the second class.
Several HDAC inhibitors are used in clinics or clinical
trials. Although many are non-selective and block the activity
of all HDACs, some are selective against class I or II
HDACs. FK228, a small HDAC inhibitor against HDACs
from Class I, was demonstrated to be the most potent with
regard to a reduction in ovarian cancer cell growth (39).
Vorinostat and trichostatin are well known clinically-used
HDACi that enhance the cytotoxicity of DNA-targeting drugs
(i.e. cisplatin and doxorubicin) (40). Studies from our
laboratory have also shown that therapy with HDAC
inhibitors such as valproic acid and standard anti-ovarian
cancer drugs could be promising treatments (41). PXD101
was shown to act as a single-agent anti-tumour drug in A2780
xenografts, and its effects were enhanced when combined
with carboplatin (42). Also, in other cancers such as renal cell
carcinoma, HDACs synergise an anti-proliferative effect of
chemotherapeutic drugs (43). Another HDAC inhibitor,
belinostat, seems to be synergistic with carboplatin and
paclitaxel; such a combination was better tolerated than a
single therapy (44). Also important during treatment, normal
cells are relatively resistant to the effects of HDAC inhibitors
(45). The multi-potent role of HDAC inhibitors makes them
promising factors in ovarian cancer treatment.
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Figure 3. Effect of leptin at a dose of 40 ng/mL and leptin receptor antagonists (SHLA and Lan2) on total histone deacetylase activity. Each point
represents the mean±SEM of three independent experiments of four replicates per treatment group. Statistically significant different values are
indicated with different letters; the same letters indicating no significant differences, with a<b<c.
In conclusion, this study showed that leptin can impact on
the expression of HDAC genes and proteins in certain
ovarian cancer cells. We also suggest that both SHLA and
Lan-2, selective leptin receptor antagonists, could exhibit
some benefits in ovarian cancer treatment, because they are
able to decrease the levels of HDACs.
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